Article

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

2021-04-01

Abstract excerpt

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and therapeutic antibodies underscores the urgent need for new antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells of COVID-19 patients. The three most potent antibodies targeted dist...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2d4c4e5c-143d-5ad3-be1a-6158cbac81df
DOI: 10.1101/2021.04.01.437942

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsDOI 10.1101/2021.04.01.437942Read

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concernSemantic proximity Read

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617Semantic proximity Read

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617Semantic proximity Read

Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational lockingSemantic proximity Read

Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variantsSemantic proximity Read

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2Semantic proximity Read

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralizationSemantic proximity Read

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsSemantic proximity Read

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.Semantic proximity Read

Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody CocktailSemantic proximity Read

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.Semantic proximity Read